Integra LifeSciences Announces Launch of LUXTEC UltraLite Pro Headlight
PLAINSBORO, N.J., May 11, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the introduction of the LUXTEC(R) UltraLite(R) Pro headlight for use in surgical procedures, the latest addition to Luxtec's extensive line of illumination systems. Integra will feature the LUXTEC(R) UltraLite(R) Pro headlight at the American Association for Thoracic Surgery 89th Annual Meeting, May 9-13th, 2009, in Boston, MA.
The LUXTEC(R) UltraLite(R) Pro headlight is a revolutionary headlight, engineered for comfort and stability. The key criterion in headlight design is surgeon comfort. The 10% weight reduction and three point adjustment design includes an occipital basket adjustment, a cranial pad adjustment and a head band adjustment. Taken together, these balance the weight of the headlight, and reduce neck strain and temporal compression. The UltraLite(R) Pro headlight also features a new and improved light module for 10% more light output
Most surgical procedures require directed white light to visualize blood vessels, muscle tissue and specific anatomical features. Thousands of surgeons worldwide use LUXTEC(R) headlights for optimal surgical site visualization.
"We're very pleased that we have designed a headlight that provides more comfort for the surgeon and enhances Luxtec's already excellent illumination capabilities," said Debbie Leonetti, President of Integra Surgical. "Our new UltraLite(R) Pro headlight, combined with our new MLX300 Watt Xenon light source, provides surgeons with superior color fidelity and proven quality and reliability."
The Integra Surgical direct sales organization and distributor network will sell the LUXTEC(R) UltraLite(R) Pro headlight. Integra Surgical is a leading provider of Jarit(R) brand surgical instruments, used in general, neurosurgery, cardiac surgery and most other surgical modalities, the Omni-Tract(R) family of retractor systems, and the LUXTEC(R) illumination products. For more information, visit www.integrasurgical.com
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of clinically relevant, innovative, and cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, orthopedics and general surgery, are used to treat millions of patients every year. The company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information, visit www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
IART-P
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.
Integra LifeSciences Holdings Corporation
Gianna Sabella, Director of Corporate Communications
(609) 936-2389
gsabella@integra-LS.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX